Barclays Holds Blueprint Medicines at $129

Barclays analyst Peter Lawson maintains a Hold rating on Blueprint Medicines with a $129.00 price target. The company's shares closed at $128.40. Analysts have a Hold consensus rating for BPMC with a $131.00 average price target. BPMC market cap is $8.3B and has a P/E ratio of -52.17. Corporate insider activity shows a negative sentiment, with 57 insiders selling shares over the past quarter.

Blueprint Medicines (BPMC) has seen a mixed reaction from analysts, with a consensus rating of Moderate Buy and a price target of $131.00, according to MarketBeat [1]. The company's shares closed at $128.40 on July 2, 2025, with a market capitalization of $8.3 billion and a P/E ratio of -52.17, indicating negative earnings. Analysts have expressed varying sentiments, with some maintaining a Hold rating, including Barclays analyst Peter Lawson, who has set a price target of $129.00.

The company's earnings are expected to grow from ($3.68) to ($1.44) per share in the coming year [1]. However, the P/B Ratio of 49.50 suggests that the company might be overvalued compared to its assets and liabilities [1]. Additionally, 8.03% of the outstanding shares have been sold short, indicating a bearish sentiment among investors [1].

In contrast, Cogent Biosciences (COGT) has seen a significant boost in its stock price following positive trial results for bezuclastinib, a drug for systemic mastocytosis. Leerink Partners raised its price target on COGT to $18.00 from $16.00, citing strong trial data and a positive safety profile [2]. The SUMMIT Part 2 trial showed an 8.91-point placebo-adjusted benefit on the primary endpoint, surpassing the "home run" scenario described by management [2].

While COGT's results have generated optimism, Blueprint Medicines faces challenges. The company has seen increased short interest, with a 12.58% increase in the past month, indicating a decrease in investor sentiment [1]. Additionally, corporate insider activity shows a negative sentiment, with 57 insiders selling shares over the past quarter [1].

In conclusion, Blueprint Medicines faces a mixed outlook from analysts, with varying sentiments and price targets. The company's earnings growth is expected, but its high P/B Ratio and negative earnings raise concerns. Meanwhile, Cogent Biosciences' positive trial results have boosted investor confidence in its drug candidate, bezuclastinib.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/BPMC/
[2] https://in.investing.com/news/analyst-ratings/cogent-stock-price-target-raised-to-18-by-leerink-on-positive-trial-data-93CH-4902447